open access

Vol 9, No 4 (2007)
Published online: 2008-02-12
Get Citation

Results of percutaneous transluminal angioplasty in patients with TASC A femoropopliteal lesions

Robert Juszkat, Fryderyk Pukacki, Bartosz Żabicki, Grzegorz Oszkinis, Marcin Gabriel, Jerzy Kulesza, Ryszard Staniszewski, Wacław Majewski
Chirurgia Polska 2007;9(4):193-201.

open access

Vol 9, No 4 (2007)
Published online: 2008-02-12

Abstract

Background: The objective of the study was an evaluation of percutaneous transluminal angioplasty (PTA) as a method of revascularization in TASC A femoropopliteal lesions.
Material and methods: Endovascular treatment was performed in 77 patients with symptomatic PAD because of TASC A femoropopliteal lesions. Patients qualified to undergo the procedure presented symptoms of PAD during anamnesis or physical examination. Additionally, the measurement of ankle/brachial index (ABI), Duplex Doppler examination and digital subtractive angiography were performed. PTA was carried out in all cases while in 9 (10.9%) additional stenting was required because of dissection. Results were monitored on the 3rd day after the procedure on the basis of physical examination, ABI estimation and Duplex Doppler. A follow-up was performed in a period of 6 to 18 months after the procedure.
Results: Technical success was achieved in 82 (100%) cases. Hemodynamic efficacy was obtained at a level of 92.7% on the 3rd day after PTA. A distant follow-up was performed in 71 patients (75 limbs). In 91% (68/75) of limbs unimpeded flow was confirmed. Occlusion of the vessel was detected in 5% and restenosis in 4% of cases. PTA alone is an effective method to treat TASC A femoropopliteal lesions. Stenting is indicated only if suboptimal PTA or dissection occurs.

Abstract

Background: The objective of the study was an evaluation of percutaneous transluminal angioplasty (PTA) as a method of revascularization in TASC A femoropopliteal lesions.
Material and methods: Endovascular treatment was performed in 77 patients with symptomatic PAD because of TASC A femoropopliteal lesions. Patients qualified to undergo the procedure presented symptoms of PAD during anamnesis or physical examination. Additionally, the measurement of ankle/brachial index (ABI), Duplex Doppler examination and digital subtractive angiography were performed. PTA was carried out in all cases while in 9 (10.9%) additional stenting was required because of dissection. Results were monitored on the 3rd day after the procedure on the basis of physical examination, ABI estimation and Duplex Doppler. A follow-up was performed in a period of 6 to 18 months after the procedure.
Results: Technical success was achieved in 82 (100%) cases. Hemodynamic efficacy was obtained at a level of 92.7% on the 3rd day after PTA. A distant follow-up was performed in 71 patients (75 limbs). In 91% (68/75) of limbs unimpeded flow was confirmed. Occlusion of the vessel was detected in 5% and restenosis in 4% of cases. PTA alone is an effective method to treat TASC A femoropopliteal lesions. Stenting is indicated only if suboptimal PTA or dissection occurs.
Get Citation

Keywords

TASC; angioplasty; percutaneous; PTA; peripheral; femoropopliteal

About this article
Title

Results of percutaneous transluminal angioplasty in patients with TASC A femoropopliteal lesions

Journal

Chirurgia Polska (Polish Surgery)

Issue

Vol 9, No 4 (2007)

Pages

193-201

Published online

2008-02-12

Bibliographic record

Chirurgia Polska 2007;9(4):193-201.

Keywords

TASC
angioplasty
percutaneous
PTA
peripheral
femoropopliteal

Authors

Robert Juszkat
Fryderyk Pukacki
Bartosz Żabicki
Grzegorz Oszkinis
Marcin Gabriel
Jerzy Kulesza
Ryszard Staniszewski
Wacław Majewski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaBy "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl